Loading…
Loading grant details…
| Funder | Vinnova |
|---|---|
| Recipient Organization | Uppsala University |
| Country | Sweden |
| Start Date | Oct 01, 2021 |
| End Date | Mar 17, 2022 |
| Duration | 167 days |
| Number of Grantees | 1 |
| Roles | Principal Investigator |
| Data Source | Swedish Research Council |
| Grant ID | 2021-03475_Vinnova |
Purpose and goal: ** Denna text är maskinöversatt **
The aim of the project was to increase the number of primary tumor types tested in animals in order to strengthen the possibility of a more effective EU proposal. The call from the EU is intended to develop multifunctional biomaterials that can be used for several applications, one of which should be highlighted as a more specific example with a business plan, scaling up, preparing GMP production and clarifying the regulatory path towards the clinic.
Expected results and effects: ** Denna text är maskinöversatt **
The results were delayed and could not be used to strengthen proposal. However, the results showed / indicated that several tumor types can be treated and that more delivery routes than intravenous delivery are possible, which is very promising for the future. Approach and implementation: ** Denna text är maskinöversatt **
Production and characterization of heparin-based nanoparticles followed plan as described in proposal. Sterile lyophilized particles were delivered in time to animal studies.
Glioblastoma cells were transduced with lentivirus to express Luciferase for non-invasive determination of tumor volume with IVIS camera and transplanted into the brain of mice. T15 days after transplantation of tumor into the mouse brain, the tumor in the reference group had grown so much that the experiment had to be terminated due to ethical considerations.
Uppsala University
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant